Summarized by Masters of Longevity from Longevity Technology.
Seragy secured €12 million to expand its SeRAS biomarker lab and analytics capacity.
Key Takeaways
- The financing is €12 million in mixed debt, equity and public funds.
- SeRAS is a quantitative platform for protein aggregation subtyping.
- No clinical performance data are reported; efficacy remains unproven.
